1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

PharmaPoint: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Global Drug Forecast and Market Analysis to 2024

  • December 2015
  • 427 pages
  • GlobalData
Report ID: 3706442

Summary

Table of Contents

Search Inside

PharmaPoint: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Global Drug Forecast and Market Analysis to 2024

Summary

With the discovery of penicillin, the first naturally-occurring antibiotic, in 1928, and its mass production in the early 1940s, infections with Staphylococcus aureus were mostly treatable, without any major complications. However, clinicians soon observed the emergence of penicillin-resistant strains of S. aureus, which was largely driven by bacterial expression of beta-lactamases. Methicillin, a novel penicillin analogue that was resistant to beta-lactamases, was introduced in 1959, and was initially effective against penicillin-resistant S. aureus strains. However, this success was short-lived, as the first methicillin-resistant S. aureus (MRSA) strain had been identified in the lab by 1961, and cases of MRSA were first observed in the clinic in 1968. Initially, MRSA strains only occurred in small and local outbreaks across the US and Europe, but they can now be found around the world.

Today, the MRSA market is highly competitive, as physicians have a myriad of antimicrobial agents at their disposal that are approved to treat these severe and often life-threatening infections. There are currently over 10 marketed antibiotics that have demonstrated potent activity against MRSA, which are frequently used to treat invasive infections in the hospital setting. GlobalData projects the global MRSA marketplace - which, for the purposes of this report, includes patients hospitalized with MRSA skin infections, pneumonia, or bacteremia in the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) - to experience limited growth from 2014-2024.

Highlights

Key Questions Answered

- How will the MRSA therapeutics market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2014-2024?
- What are the most promising late-stage pipeline drugs for MRSA?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the key unmet needs in MRSA treatment landscape?
- What drivers and barriers will influence MRSA therapeutics sales in the 7MM over the forecast period?

Key Findings

- The global MRSA marketplace, which, for the purposes of this report, includes patients hospitalized with MRSA skin infections, pneumonia, or bacteremia in the 7MM, was worth approximately $1.40 billion in 2014. GlobalData projects the market to exceed $1.45 billion in sales by 2024, at a Compound Annual Growth Rate (CAGR) of 0.4% from 2014-2024. These sales are projected to originate predominantly from the US (with a 71% market share), followed distantly by Japan (with a 16% market share).
- The recent and expected launches of novel antimicrobial agents with potent activity against MRSA, led by Allergan’s Dalvance (dalbavancin), Merck’s Sivextro (tedizolid phosphate), The Medicines Company’s Orbactiv (oritavancin), Debiopharm’s Debio1450, and Nabriva’s lefamulin, will be a principal driver of MRSA drug sales growth across the 7MM from 2014-2014.
- Competition from generics manufacturers, spurred on by the anticipated loss of patent protection for the market leaders Zyvox (linezolid) and Cubicin (daptomycin), will serve as a formidable barrier to growth for the duration of the forecast period.

Scope

- Overview of MRSA infections, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline MRSA market revenue from 2014-2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting MRSA therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global MRSA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global MRSA therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the MRSA therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Penicillin and Streptomycin Markets in the World to 2021 - Market Size, Development, and Forecasts

  • $ 23395
  • Industry report
  • July 2017
  • by Global Research & Data Services

The industry report package Penicillin and Streptomycin Markets in the World to 2021 - Market Size, Development, and Forecasts offers the most up-to-date market data on the actual market situation, and ...

Penicillin and Streptomycin Markets in Europe to 2021 - Market Size, Development, and Forecasts

  • $ 12090
  • Industry report
  • July 2017
  • by Global Research & Data Services

The industry report package Penicillin and Streptomycin Markets in Europe to 2021 - Market Size, Development, and Forecasts offers the most up-to-date market data on the actual market situation, and future ...

Penicillin and Streptomycin Markets in Asia to 2021 - Market Size, Development, and Forecasts

  • $ 9031
  • Industry report
  • July 2017
  • by Global Research & Data Services

The industry report package Penicillin and Streptomycin Markets in Asia to 2021 - Market Size, Development, and Forecasts offers the most up-to-date market data on the actual market situation, and future ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.